Sports Medicine Research And Testing Laboratory

Sports Medicine Research and Testing Laboratory (SMRTL), a non-profit, WADA-accredited small business headquartered in South Jordan, Utah, delivers specialized analytical drug testing services to the Department of Defense as a prime contractor—100% of its federal footprint comprises direct prime awards with zero subcontracting activity. The vendor operates as a single-award IDC holder and delivers performance-enhancing drug testing, steroid analysis, and isotopic ratio mass spectrometry (IRMS) testing from laboratory facilities in Riverton, Utah and Fort Meade, Maryland, with all work issued under Department of Defense contracting vehicles carrying no set-aside designations.

SMRTL's customer base is heavily concentrated in naval medical operations. The Department of the Navy Bureau of Medicine and Surgery accounts for 139 of 155 awards (97% coverage) and $35.5 million of the vendor's $38.3 million combined potential value, leaving virtually no diversification across the remaining eight federal customers. The Defense Health Agency places five awards totaling $125 thousand; the Department of Justice Drug Enforcement Administration holds six awards for $56 thousand; the Department of the Army Medical Command holds four awards for $59 thousand; and the Department of Homeland Security Coast Guard has placed one purchase order for $6.2 thousand. The two ranking systems align completely — Navy BUMED dominates both award count and dollars, and no tension exists between volume and value concentration.

The vendor holds multiple single-award IDCs with Navy BUMED anchoring the recent contract footprint. The most recent and largest vehicle is an August 2025 award with a $13.1 million ceiling running through August 2028 for Naval Special Warfare performance-enhancing drug testing, under which a $4.0 million delivery order was issued in September 2025 to support NSW operations through September 2026. An August 2023 single-award IDC valued at $10.4 million supports base NSW PED testing through February 2026 and has generated two firm fixed-price delivery orders: one for $4.0 million (August 2024) and another for $2.4 million (September 2023). A third Navy BUMED IDC awarded August 2023 carries a $1.76 million ceiling through August 2028 for broader multi-service testing across Army, Air Force, and the Armed Forces Medical Examiner. The four largest Navy BUMED IDCs (N6264523D5012, N0018925DZ033, and others) collectively represent $6.5 million and $4.0 million in singular major delivery orders. Beyond these, SMRTL operates under two additional Navy BUMED indefinite delivery contracts that have generated 99 and 34 task orders respectively, though those vehicles now carry minimal remaining ceiling values of $282 thousand and $14 thousand combined.

Activity shows a sharp contraction. The vendor delivered 27 awards in 2023, 15 in 2022, but only three in 2024, four in 2025, and one award in 2026 year-to-date. Only one award reaches ultimate completion within the next twenty-four months—a $56 thousand DEA commitment—leaving minimal recompete exposure in the near term, though the vendor's dominant Navy BUMED vehicles will require recompetes in late 2026 and 2028. Representative recent work includes the June 2025 Navy BUMED $4.0 million delivery order for Naval Special Warfare PED testing with capacity to process 1,200 specimens monthly and conduct 19,000 annual initial tests through September 2026, and a June 2026 Defense Health Agency $55.8 thousand delivery order for Fort Meade Army drug screening operations through June 2027. All awards are firm fixed price with no set-asides and no subcontracting; SMRTL operates as a specialized monopoly provider for this narrow federal requirement.